News

This FDA News Month in Review provides a round-up of regulatory decisions from April 2026.

Fukami, MD, discusses how first-line ESD may offer both survival and cost advantages over esophagectomy for EEC in the United States.

This episode covers recent advancements in treating type 1 diabetes, including the Tandem AID system for pregnant women and teplizumab for adolescents.

Chedid, MD, MS, explains the evolving therapeutic IBD landscape, including new data from DDW 2026.

Chedid describes the future of personalizing IBD care based on patient characteristics.

Ahmad Masri, MD, from OHSU, discusses the positive topline results from this phase 3 trial, highlighting a new path forward for nHCM.

Noureddin discusses HU6’s mitochondrial uncoupling mechanism and why muscle preservation may become increasingly important in MASH care.

Catch up on updates in viral hepatitis treatment, advances in rare liver disease care, and more.

Catch up on new IBD drug trial data, regulatory actions, and updates in IBS in this April month in review.

Juanita Mora, MD, discusses The American Lung Association's 2026 report, elucidating a disproportionate burden on people of color.

Patient education may be the missing piece needed to bridge the gap between hypertension treatments and improved outcomes.

Early data suggest varenicline may improve abdominal pain, bloating, and bowel symptoms in patients with IBS.

In 38 patients with house dust mite allergy, 18 months of SLIT was linked to early expansion and later reduction of allergen-specific type 2 memory B cells.

Colombel discusses long-term LUCENT extension data showing durable clinical, endoscopic, and histologic outcomes with mirikizumab in moderately to severely active UC.

Dellon explains phase 4 REMODEL trial data showing dupilumab’s impact on esophageal distensibility and the underlying remodeling process in eosinophilic esophagitis.

ICI colitis linked to high rehospitalization, ICU use, and mortality even after therapy discontinuation.

Perez discusses the next steps before a marker like monocyte epigenetic age acceleration could be considered clinically actionable for precision psychiatry in depression.

Hear Andrew Sauer, MD, discuss how he broke through mental health challenges to become one of the leading voices in transplant cardiology.

Despite a growing armamentarium of approved IBD therapies, outcomes remain suboptimal. Rubin explains how earlier treatment and smarter optimization can close the gap.

In this interview, Chovatiya highlights several key takeaways regarding the latest definitions highlighted by the International Eczema Council.

Interview with Perez on how monocyte-derived epigenetic clocks outperform multi-tissue models in detecting symptom-specific depression signals.

Laurent Peyrin-Biroulet, MD, PhD, breaks down FUZION data demonstrating meaningful fistula healing with guselkumab in Crohn’s disease patients with perianal disease.

Routine depression and anxiety screening in IBD clinics was tied to significantly more referrals and sustained follow-up with psychogastroenterology services

The severe asthma treatment landscape has entered a period of rapid evolution — with patient access and adherence increasingly driving clinical decisions.

The new recommendations outline glucocorticoid tapering strategies for adults and children with classic CAH after starting crinecerfont.

Noreen Galaria, MD, highlighted the evolving role of internal photoprotection alongside practical, habit-based strategies to support physician wellness and reduce burnout.

This segment of the latest episode of the Skin of Color Savvy podcast highlights key challenges faced by Galaria in her dermatology practice.